# Shanghai Junshi Biosciences

Source: https://onco.cc/companies/junshi/  
OnCo record `junshi` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer).

## Summary

Toripalimab (Tuoyi / Loqtorzi) has more than ten NMPA indications, US approval for nasopharyngeal carcinoma with Coherus (licence February 2021, $150 million upfront), and EU, UK and Australian approvals. Pipeline: the BTLA antibody tifcemalimab, a PD-1 x VEGF bispecific and ADCs. Junshi also co-developed the COVID-19 antibody etesevimab with Lilly.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: Junshi; 君实生物
- Tags: china
- HQ: Shanghai
- Type: biotech
- Website: https://www.junshipharma.com/en/
- Ticker: 1877.HK / 688180.SS

## Sources

- Official website: https://www.junshipharma.com/en/
- Coherus licence (February 2021): https://investors.coherus.com/news-releases

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Fluzoparib](https://onco.cc/drugs/fluzoparib/), [JS105](https://onco.cc/drugs/js105/), [JS111](https://onco.cc/drugs/js111/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- trials: [A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors](https://onco.cc/trials/nct06208410/), [A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer](https://onco.cc/trials/nct06885385/), [A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct07207070/), [A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat](https://onco.cc/trials/nct06679985/), [JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）](https://onco.cc/trials/nct06505837/), [JS207 Combination Therapy in Triple-negative Breast Cancer](https://onco.cc/trials/nct07045311/), [JS212 Combination Therapies in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07503756/), [JUPITER-02](https://onco.cc/trials/jupiter-02/), [JUPITER-06](https://onco.cc/trials/jupiter-06/), [Neotorch](https://onco.cc/trials/neotorch/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/junshi.json